Business Milestones
2026.03.17
TAHO Pharmaceuticals Announces Grant of Korean Patent for BEQIA
TAHO Pharmaceuticals Announces Grant of Korean Patent for BEQIA
Taipei, Taiwan – [March 13, 2026] – TAHO Pharmaceuticals Ltd. today announced that the Ministry of Intellectual Property (MOIP), has granted a patent covering BEQIA, the company’s oral film technology product. The grant of the Korean patent adds to TAHO’s growing international patent portfolio for BEQIA and provides additional exclusivity in one of Asia’s major pharmaceutical markets. TAHO continues to pursue patent protection in other key jurisdictions to support future development and potential partnerships. Oral film technology of apixaban offers several advantages over conventional dosage forms, including rapid dissolution, ease of administration without water, and improved patient compliance, particularly for patients who have difficulty swallowing tablets. TAHO Pharmaceuticals remains focused on advancing its pipeline of oral dissolving film-based therapeutics, aiming to provide more convenient and patient-friendly treatment options.
About BEQIA
BEQIA, the world’s first Apixaban oral dissolving film (ODF), is a groundbreaking product developed by TAHO Pharmaceuticals Ltd. Utilizing TAHO’s Transepithelial Delivery System (TDS), BEQIA dissolves instantly in the mouth without the need for water, providing a convenient, user- friendly experience for stroke survivors, the elderly, and others who face challenges swallowing pills.
Media Contact:
TAHO Pharmaceuticals
+886-2-2659-8515
[email protected]
Taipei, Taiwan – [March 13, 2026] – TAHO Pharmaceuticals Ltd. today announced that the Ministry of Intellectual Property (MOIP), has granted a patent covering BEQIA, the company’s oral film technology product. The grant of the Korean patent adds to TAHO’s growing international patent portfolio for BEQIA and provides additional exclusivity in one of Asia’s major pharmaceutical markets. TAHO continues to pursue patent protection in other key jurisdictions to support future development and potential partnerships. Oral film technology of apixaban offers several advantages over conventional dosage forms, including rapid dissolution, ease of administration without water, and improved patient compliance, particularly for patients who have difficulty swallowing tablets. TAHO Pharmaceuticals remains focused on advancing its pipeline of oral dissolving film-based therapeutics, aiming to provide more convenient and patient-friendly treatment options.
About BEQIA
BEQIA, the world’s first Apixaban oral dissolving film (ODF), is a groundbreaking product developed by TAHO Pharmaceuticals Ltd. Utilizing TAHO’s Transepithelial Delivery System (TDS), BEQIA dissolves instantly in the mouth without the need for water, providing a convenient, user- friendly experience for stroke survivors, the elderly, and others who face challenges swallowing pills.
Media Contact:
TAHO Pharmaceuticals
+886-2-2659-8515
[email protected]